Study #2024-0522
A Phase II open-label study of Olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Olutasidenib
Description
The goal of this clinical research study is to learn about the safety and tolerability of giving olutasidenib to patients with IDH1-mutated myeloid malignancies as maintenance therapy after they receive a stem cell transplant.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloid Malignancies
Study phase:
Phase II
Physician name:
Jeremy Ramdial
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-844-939-2381
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.